サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1538518

脂質異常症治療薬市場レポート：2030年までの動向、予測、競合分析

Dyslipidaemia Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

脂質異常症治療薬市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脂質異常症治療薬の動向と予測

世界の脂質異常症治療薬市場は、2024年から2030年までのCAGRが9.4%で、2030年までに推定440億米ドルに達すると予測されます。この市場の主な促進要因は、糖尿病および脂質異常症患者数の増加、世界の高齢者数の増加、コレステロール値異常および脂質関連疾患の頻度増加です。世界の脂質異常症治療薬市場の将来は、病院薬局と小売薬局市場に機会があり、有望視されています。

セグメント別脂質異常症治療薬

本調査では、脂質異常症治療薬の世界市場を薬剤タイプ別、用途別、地域別に予測しています。

脂質異常症治療薬市場の洞察

Lucintel社の予測では、スタチン系薬剤は予測期間中に高い成長が見込まれます。

この市場において、病院薬局は予測期間中、より大きなセグメントであり続けると思われます。

北米は予測期間中最も高い成長が見込まれます。

よくある質問

Q1.市場規模は：

A1.世界の脂質異常症治療薬市場は、2030年までに推定440億米ドルに達する見込みです。

Q2.市場の成長予測は：

A2.世界の脂質異常症治療薬市場は、2024年から2030年にかけてCAGR 9.4%で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、糖尿病および脂質異常症患者数の増加、世界の高齢者数の増加、コレステロール値異常および脂質関連疾患の頻度増加です。

Q4.市場の主要セグメントは：

A4.脂質異常症治療薬市場の将来は、病院薬局市場および小売薬局市場における機会により有望です。

Q5.市場の主要企業は：

A5.脂質異常症治療薬の主要企業は以下の通りです：

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、スタチン系薬剤が予測期間中に高い成長を遂げると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.予測期間中、北米が最も高い成長が見込まれます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の脂質異常症治療薬市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の脂質異常症治療薬市場の動向（2018～2023年）と予測（2024～2030年）
  • 薬剤タイプ別脂質異常症治療薬の世界市場
    • 非スタチン系薬剤
    • スタチン系薬剤
  • 用途別脂質異常症治療薬の世界市場
    • 病院薬局
    • 小売薬局
    • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

  • 地域別の脂質異常症治療薬の世界市場
  • 北米の脂質異常症治療薬市場
  • 欧州の脂質異常症治療薬市場
  • アジア太平洋の脂質異常症治療薬市場
  • その他地域の脂質異常症治療薬市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 業務統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 世界の脂質異常症治療薬市場における薬剤タイプ別の成長機会
    • 用途別の脂質異常症治療薬市場における成長機会
    • 地域別の世界の脂質異常症治療薬市場の成長機会
  • 世界の脂質異常症治療薬市場の新たな動向
  • 戦略分析
    • 新製品開発
    • 世界の脂質異常症治療薬市場の能力拡大
    • 世界の脂質異常症治療薬市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories
目次

Dyslipidaemia Drug Trends and Forecast

The future of the global dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Dyslipidaemia Drug by Segment

The study includes a forecast for the global dyslipidaemia drug by drug type, application, and region.

Dyslipidaemia Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Non-Statins Drugs
  • Statins Drugs

Dyslipidaemia Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Dyslipidaemia Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Dyslipidaemia Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dyslipidaemia drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dyslipidaemia drug companies profiled in this report include-

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Dyslipidaemia Drug Market Insights

Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Within this market, hospital pharmacy will remain larger segment over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Dyslipidaemia Drug Market

Market Size Estimates: Dyslipidaemia drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dyslipidaemia drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Dyslipidaemia drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the dyslipidaemia drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dyslipidaemia drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the dyslipidaemia drug market size?

Answer: The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030.

Q2. What is the growth forecast for dyslipidaemia drug market?

Answer: The global dyslipidaemia drug market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the dyslipidaemia drug market?

Answer: The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

Q4. What are the major segments for dyslipidaemia drug market?

Answer: The future of the dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets.

Q5. Who are the key dyslipidaemia drug market companies?

Answer: Some of the key dyslipidaemia drug companies are as follows:

  • AstraZeneca
  • Bayer
  • Amgen
  • Merck
  • Shionogi
  • Novartis
  • Pfizer
  • Bristol-Myers Squibb Company
  • Mylan
  • Abbott Laboratories

Q6. Which dyslipidaemia drug market segment will be the largest in future?

Answer: Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Q7. In dyslipidaemia drug market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the dyslipidaemia drug market by drug type (non-statins drugs and statins drugs), application (hospital pharmacy, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dyslipidaemia Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Dyslipidaemia Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Dyslipidaemia Drug Market by Drug Type
    • 3.3.1: Non-Statins Drugs
    • 3.3.2: Statins Drugs
  • 3.4: Global Dyslipidaemia Drug Market by Application
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Dyslipidaemia Drug Market by Region
  • 4.2: North American Dyslipidaemia Drug Market
    • 4.2.1: North American Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.2.2: North American Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.3: European Dyslipidaemia Drug Market
    • 4.3.1: European Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.3.2: European Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.4: APAC Dyslipidaemia Drug Market
    • 4.4.1: APAC Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.4.2: APAC Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
  • 4.5: ROW Dyslipidaemia Drug Market
    • 4.5.1: ROW Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
    • 4.5.2: ROW Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Dyslipidaemia Drug Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Dyslipidaemia Drug Market by Application
    • 6.1.3: Growth Opportunities for the Global Dyslipidaemia Drug Market by Region
  • 6.2: Emerging Trends in the Global Dyslipidaemia Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Dyslipidaemia Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dyslipidaemia Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AstraZeneca
  • 7.2: Bayer
  • 7.3: Amgen
  • 7.4: Merck
  • 7.5: Shionogi
  • 7.6: Novartis
  • 7.7: Pfizer
  • 7.8: Bristol-Myers Squibb Company
  • 7.9: Mylan
  • 7.10: Abbott Laboratories